Should I buy or sell Amphastar Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks .

What is Amphastar Pharmaceuticals' stock price target for 2024?

4 analysts have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $60.00 to $71.00. On average, they expect the company's share price to reach $66.00 in the next twelve months. This suggests a possible upside of 70.8% from the stock's current price. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts .

How have AMPH shares performed in 2024?

Amphastar Pharmaceuticals' stock was trading at $61.85 at the beginning of 2024. Since then, AMPH stock has decreased by 37.5% and is now trading at $38.65. View the best growth stocks for 2024 here .

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our AMPH earnings forecast .

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $0.81 earnings per share for the quarter, missing analysts' consensus estimates of $0.84 by $0.03. The business earned $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a trailing twelve-month return on equity of 26.95%.

What ETFs hold Amphastar Pharmaceuticals' stock?

ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Innovator IBD 50 ETF (FFTY) , Invesco Pharmaceuticals ETF (PJP) , SPDR S&P Pharmaceuticals ETF (XPH) , Janus Henderson Small Cap Growth Alpha ETF (JSML) , ERShares NextGen Entrepreneurs ETF (ERSX) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , Invesco S&P SmallCap Health Care ETF (PSCH) and iShares U.S. Pharmaceuticals ETF (IHE) .

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com . Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA) , Gilead Sciences (GILD) , Amicus Therapeutics (FOLD) , Exelixis (EXEL) , CNX Resources (CNX) , Immunomedics (IMMU) , AbbVie (ABBV) , Cellectis (CLLS) , Clovis Oncology (CLVS) and Galectin Therapeutics (GALT) .

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.13%), Bridge City Capital LLC (0.07%), Annex Advisory Services LLC (0.03%), Juncture Wealth Strategies LLC (0.02%), Guidance Capital Inc. (0.02%) and Hennion & Walsh Asset Management Inc. (0.02%). Insiders that own company stock include Diane G Gerst , Floyd F Petersen , Howard Lee , Jack Y Zhang , Mary Z Luo , Michael A Zasloff , Richard K Prins , Richard Koo , Rong Zhou , William J Peters and Yakob Liawatidewi . View institutional ownership trends .

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AMPH

Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AMPH Stock Alerts

$38.65

-1.40 (-3.50%)

(As of 04/18/2024 ET)

Compare

Today's Range: $38.44
▼
$40.02
50-Day Range: $39.62
▼
$56.02
52-Week Range: $35.62
▼
$67.66

Volume: 329,460 shs
Average Volume: 464,474 shs
Market Capitalization: $1.89 billion

P/E Ratio: 14.98
Dividend Yield: N/A
Price Target: $66.00

Get Amphastar Pharmaceuticals alerts:

Amphastar Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 70.8% Upside
$66.00 Price Target
Short Interest: Bearish
10.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.21
Upright™ Environmental Score
News Sentiment: 0.73
Based on 8 Articles This Week
Insider Trading: Selling Shares
$660,860 Sold Last Quarter
Proj. Earnings Growth: 20.18%
From $3.42 to $4.11 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.79 out of 5 stars

Medical Sector

41st out of 919 stocks

Pharmaceutical Preparations Industry

10th out of 405 stocks

3.3

Analyst's Opinion

Consensus Rating
Amphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Amphastar Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.63% of the float of Amphastar Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in Amphastar Pharmaceuticals has recently increased by 1.94%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Amphastar Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Amphastar Pharmaceuticals does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Amphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.
Environmental Sustainability
The Environmental Impact score for Amphastar Pharmaceuticals is -2.21.

2.6

News and Social Media Coverage

News Sentiment
Amphastar Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 10 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -65% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $660,860.00 in company stock.
Percentage Held by Insiders
28.40% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.8

Earnings and Valuation

Earnings Growth
Earnings for Amphastar Pharmaceuticals are expected to grow by 20.18% in the coming year, from $3.42 to $4.11 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amphastar Pharmaceuticals is 14.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.94.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amphastar Pharmaceuticals is 14.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 227.61.
Price to Earnings Growth Ratio
Amphastar Pharmaceuticals has a PEG Ratio of 0.98. PEG Ratios around 1 indicate that a company is correctly valued.
Price to Book Value per Share Ratio
Amphastar Pharmaceuticals has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AMPH Stock News Headlines

April 4, 2024 | insidertrades.com

Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 500 Shares of Stock

April 18, 2024 | markets.businessinsider.com

Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | finance.yahoo.com

Naloxone Market To Reach USD 2,478.6 Million By 2032 | DataHorizzon Research

April 12, 2024 | finance.yahoo.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) shareholders YoY returns are lagging the company's 66% three-year earnings growth

April 11, 2024 | americanbankingnews.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns "Hold" Rating from Needham & Company LLC

April 9, 2024 | msn.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity

April 4, 2024 | msn.com

Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 18, 2024 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Soleno Therapeutics (SLNO), Optinose (OPTN)

March 16, 2024 | finance.yahoo.com

AMPH Apr 2024 65.000 call

March 16, 2024 | finance.yahoo.com

AMPH Apr 2024 60.000 put

March 9, 2024 | finance.yahoo.com

Amphastar Pharmaceuticals Inc CFO, EVP & Treasurer William Peters Sells 18,136 Shares

March 8, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Oxford BioMedica (OXBDF), EyePoint Pharmaceuticals (EYPT)

March 6, 2024 | finance.yahoo.com

Amphastar Pharmaceuticals Inc Director Michael Zasloff Sells 12,500 Shares

March 6, 2024 | finanznachrichten.de

Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference

March 6, 2024 | msn.com

JP Morgan Initiates Coverage of Amphastar Pharmaceuticals (AMPH) with Overweight Recommendation

March 4, 2024 | seekingalpha.com

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

March 2, 2024 | ca.finance.yahoo.com

LLY Mar 2024 980.000 call

March 2, 2024 | finance.yahoo.com

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2023 Earnings Call Transcript

February 29, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Schrodinger (SDGR)

February 29, 2024 | finance.yahoo.com

Q4 2023 Amphastar Pharmaceuticals Inc Earnings Call

February 28, 2024 | finance.yahoo.com

Amphastar Pharmaceuticals Inc Reports Robust Revenue Growth and Strong Full-Year Performance

February 27, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Amphastar Pharmaceuticals's earnings

February 26, 2024 | msn.com

Agios Pharmaceuticals Stock Earns IBD Stock Upgrade Again, Hitting 90-Plus RS Rating

February 23, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Penumbra (PEN)

February 22, 2024 | cnn.com

Amphastar Pharmaceuticals, Inc.

See More Headlines

Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AMPH
CUSIP: N/A
CIK: 1297184
Web: www.amphastar.com
Phone: (909) 980-9484
Fax: 909-980-8296
Employees: 1,761
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $66.00
High Stock Price Target: $71.00
Low Stock Price Target: $60.00
Potential Upside/Downside: +70.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.58
Trailing P/E Ratio: 15.02
Forward P/E Ratio: 11.33
P/E Growth: 0.98
Net Income: $137.54 million
Net Margins: 21.34%
Pretax Margin: 26.59%
Return on Equity: 26.95%
Return on Assets: 12.27%

Debt

Debt-to-Equity Ratio: 0.92
Current Ratio: 2.17
Quick Ratio: 1.70

Sales & Book Value

Annual Sales: $644.40 million
Price / Sales: 2.94
Cash Flow: $4.14 per share
Price / Cash Flow: 9.37
Book Value: $13.35 per share
Price / Book: 2.90

Miscellaneous

Outstanding Shares: 48,870,000
Free Float: 34,988,000
Market Cap: $1.89 billion
Optionable: Optionable
Beta: 0.84

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Ziping Luo Ph.D. (Age 74)
Chairman of the Board, Chief Scientist & COO
Comp: $1.53M
Dr. Yongfeng Zhang Ph.D. (Age 77)
Co-Founder, President, CEO, Chief Scientific Officer & Director
Comp: $2.13M
Mr. William J. Peters M.B.A. (Age 56)
CFO, Executive VP of Finance, Treasurer & Director
Comp: $1.12M
Mr. Jacob Liawatidewi M.B.A. (Age 50)
Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
Comp: $794.15k
Mr. Rong Zhou M.S. (Age 65)
Senior Executive Vice President of Production
Comp: $835.05k
Dan Dischner M.B.A.
Vice President of Human Resources & Corporate Communication
Tony Marrs M.B.A.
M.P.H., Senior VP of Regulatory Affairs & Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMPH shares.
View AMPH analyst ratings or view top-rated stocks.
What is Amphastar Pharmaceuticals' stock price target for 2024?: 4 analysts have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $60.00 to $71.00. On average, they expect the company's share price to reach $66.00 in the next twelve months. This suggests a possible upside of 70.8% from the stock's current price.
View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts.
How have AMPH shares performed in 2024?: Amphastar Pharmaceuticals' stock was trading at $61.85 at the beginning of 2024. Since then, AMPH stock has decreased by 37.5% and is now trading at $38.65.
View the best growth stocks for 2024 here.
When is Amphastar Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AMPH earnings forecast.
How were Amphastar Pharmaceuticals' earnings last quarter?: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $0.81 earnings per share for the quarter, missing analysts' consensus estimates of $0.84 by $0.03. The business earned $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a trailing twelve-month return on equity of 26.95%.
What ETFs hold Amphastar Pharmaceuticals' stock?: ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Innovator IBD 50 ETF (FFTY), Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Janus Henderson Small Cap Growth Alpha ETF (JSML), ERShares NextGen Entrepreneurs ETF (ERSX), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH) and iShares U.S. Pharmaceuticals ETF (IHE).

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?: 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.
What other stocks do shareholders of Amphastar Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).
Who are Amphastar Pharmaceuticals' major shareholders?: Amphastar Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.13%), Bridge City Capital LLC (0.07%), Annex Advisory Services LLC (0.03%), Juncture Wealth Strategies LLC (0.02%), Guidance Capital Inc. (0.02%) and Hennion & Walsh Asset Management Inc. (0.02%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Mary Z Luo, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi.
View institutional ownership trends.
How do I buy shares of Amphastar Pharmaceuticals?: Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMPH) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial